1
Return

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial

delete2026-06-29
delete0
delete
OA
AI
T
Thomas J George *
T
Tuo Lin
I
Ibrahim Nassour
S
Sherise C Rogers
T
Tim Jang
I
Ilyas Sahin
B
Brian H Ramnaraign
J
Jesus Fabregas
K
Kathryn Hitchcock
G
Gonghao Liu
K
Karen B Russell
A
Anita A Turk
O
Omar Kayaleh
Z
Z Hugh Fan
D
David L DeRemer
R
Ryan M Thomas
J
Ji-Hyun Lee
S
Steven J Hughes
DOI：10.1093/oncolo/oyag250delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
While neoadjuvant FOLFIRINOX is an effective regimen for pancreatic ductal adenocarcinoma (PDAC), toxicity frequently limits its use. Nanoliposomal irinotecan (nal-IRI) offers improved pharmacokinetic properties and may mitigate some of the side effects. We conducted a multi-institutional, phase II study to evaluate the safety and clinical activity of neoadjuvant NALIRIFOX (nal-IRI, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with resectable and borderline resectable (R/BR) PDAC.

Journal

T
The Oncologist
IF:
0
Papers:
188
Citations:
0

Organization

U
UF Health Cancer Institute
Scholars:
6
Papers: 3
Citations: 0
O
orlando health cancer institute
Scholars:
10
Papers: 10
Citations: 0
I
indiana university simon comprehensive cancer center
Scholars:
18
Papers: 8
Citations: 0
U
university of florida
Scholars:
5.1K
Papers: 2.3K
Citations: 1
T
tallahassee memorial hospital
Scholars:
2
Papers: 1
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers